NCT04330430 2025-03-12
NIVEC
The Netherlands Cancer Institute
Phase 2 Completed
Clinical Trials
8 trialsNCT02819843 2025-01-29
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03842943 2024-05-02
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
University of Louisville
Phase 2 Recruiting
NCT04427306 2023-09-15
Neoadjuvant T-VEC in High Risk Early Melanoma
University of California, Davis
Phase 2 Suspended
NCT03555032 2021-08-18
TITAN
Royal Marsden NHS Foundation Trust
Phase 1/2 Completed
NCT03747744 2020-12-29
myDCTV
Universitair Ziekenhuis Brussel
Phase 1 Unknown
NCT03972046 2020-10-19
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
TriHealth Inc.
Phase 2 Withdrawn
NCT03088176 2020-10-12
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
West Cancer Center
Phase 1 Unknown